Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom (Podcast Pearls)

Experts from the Netherlands and the United Kingdom provide their thoughts on recent advances with immune checkpoint therapy for advanced urothelial carcinoma
person default
Thomas Powles, MBBS, MRCP, MD
Michiel van der Heijden, MD, PhD
Format: Adobe Acrobat (.pdf)
File Size: 269 KB
Released: December 10, 2020

Acknowledgements

Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Related Content

First results from PEACE-1 trial of abiraterone with or without local radiotherapy plus SOC in metastatic CSPC, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Downloadable slideset from Eric Jonasch, MD on managing irAEs in patients with advanced RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 16, 2021

Downloadable slideset from Dr Elizabeth R. Plimack on first-line treatment options for patients with RCC, from Clinical Care Options (CCO)

Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Downloadable slideset from Neeraj Agarwal, MD on treatment options for salvage therapy in advanced RCC, from Clinical Care Options (CCO)

Neeraj Agarwal, MD Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue